Literature DB >> 31042575

Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn's Disease.

Nassim Hammoudi1, Dominique Cazals-Hatem2, Claire Auzolle1, Charlotte Gardair3, Marjolaine Ngollo4, Hugo Bottois4, Stéphane Nancey5, Benjamin Pariente6, Anthony Buisson7, Xavier Treton8, Mathurin Fumery9, Madeleine Bezault4, Philippe Seksik10, Lionel Le Bourhis4, Jean-François Flejou11, Matthieu Allez12.   

Abstract

BACKGROUND AND AIMS: Different types of histologic lesions at the ileal margin, detected by histology, have been associated with increased rates of recurrence after ileocaecal surgery in patients with Crohn's disease (CD). We aimed to characterize histologic features of the ileal margin and to evaluate their association with disease recurrence.
METHODS: We collected histologic data from 211 patients with ileal or ileocolonic CD who underwent ileocolonic resections at hospitals in France from September 2010 through December 2016. Ileal margins were analyzed. Early endoscopic recurrence was defined by a Rutgeerts score of i2 or more, 6 months after surgery. We also collected data from 10 adults with healthy ileum who underwent ileocecal resection for colonic tumors (controls). Clinical relapse was defined by CD-related symptoms confirmed by imaging, endoscopy, therapy intensification, CD-related complication, or subsequent surgery.
RESULTS: Six months after surgery, 49% of patients had endoscopic recurrence; 5 years after surgery, 57% of patients had clinical relapse. Ileal margins were macroscopically affected in 20.9% of patients. CD transmural lesions at the margin (defined by mucosal ulceration or cryptitis, submucosal fibrosis and lymphoplasmacytic infiltrate of the subserosa) were observed in 13.6% of patients. Endoscopic recurrence was observed in 75% of patients with CD transmural lesions vs 46% of patients without (P =.005). In multivariate analysis, CD transmural lesions at the margin were independently associated with early endoscopic recurrence (OR, 3.83; 95% CI, 1.47-11.05; P =.008) and clinical recurrence (OR 2.04; 95% CI, 1.09-3.99; P =.026).
CONCLUSION: In patients with CD, transmural lesions at the ileal margin were associated with an increased risk of post-operative recurrence. Histologic features of the ileal margin should be included in making decisions about post-operative therapy.
Copyright © 2020 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  IBD Surgery; Outcome; Prognostic Factor; REMIND Trial

Mesh:

Year:  2019        PMID: 31042575     DOI: 10.1016/j.cgh.2019.04.045

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  4 in total

1.  State-of-the-art surgery for Crohn's disease: Part I-small intestine/ileal disease.

Authors:  Sandra L Kavalukas; Katharina M Scheurlen; Susan Galandiuk
Journal:  Langenbecks Arch Surg       Date:  2021-11-04       Impact factor: 3.445

Review 2.  Pharmacological Prevention and Management of Postoperative Relapse in Pediatric Crohn's Disease.

Authors:  Anat Yerushalmy-Feler; Amit Assa
Journal:  Paediatr Drugs       Date:  2019-12       Impact factor: 3.022

3.  The Relationship Between Endoscopic and Clinical Recurrence in Postoperative Crohn's Disease: A Systematic Review and Meta-analysis.

Authors:  Alessandro Ble; Cecilia Renzulli; Fabio Cenci; Maria Grimaldi; Michelangelo Barone; Rocio Sedano; Joshua Chang; Tran M Nguyen; Malcolm Hogan; Guangyong Zou; John K MacDonald; Christopher Ma; William J Sandborn; Brian G Feagan; Emilio Merlo Pich; Vipul Jairath
Journal:  J Crohns Colitis       Date:  2022-03-14       Impact factor: 10.020

4.  Predictive Factors of Surgical Recurrence in Patients with Crohn's Disease on Long-Term Follow-Up: A Focus on Histology.

Authors:  Gian Paolo Caviglia; Chiara Angela Mineo; Chiara Rosso; Angelo Armandi; Marco Astegiano; Gabriella Canavese; Andrea Resegotti; Giorgio Maria Saracco; Davide Giuseppe Ribaldone
Journal:  J Clin Med       Date:  2022-08-27       Impact factor: 4.964

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.